CSS LLC’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

CSS LLC’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-10,000	Closed	-$588K	–	1005
2023 Q4	$588K	Buy	+10,000	New	+$562K	0.03%	365
2022 Q4	–	Sell	-3,000	Closed	-$210K	–	1163
2022 Q3	$210K	Buy	+3,000	New	+$222K	0.01%	742
2021 Q4	–	Sell	-8,800	Closed	-$1.56M	–	1359
2021 Q3	$1.56M	Buy	8,800 +3,100	+54%	+$499K	0.07%	307
2021 Q2	$921K	Hold	5,700	–	–	0.04%	423
2021 Q1	$977K	Sell	5,700 -5,100	-47%	-$1.01M	0.04%	402
2020 Q4	$2.37M	Buy	10,800 +4,300	+66%	+$930K	0.09%	174
2020 Q3	$1.08M	Buy	+6,500	New	+$889K	0.05%	279
2020 Q2	–	Sell	-24,000	Closed	-$1.84M	–	778
2020 Q1	$1.84M	Buy	24,000 +2,300	+11%	+$206K	0.15%	138
2019 Q4	$2.8M	Buy	+21,700	New	+$2.09M	0.15%	126

Other funds holding MRTX

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

CSS LLC's MRTX Position: Q1 2024 in Review

CSS LLC sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 343,845 shares — an estimated $20.2M sold.

CSS LLC first reported a position in MRTX in Q1 2021 and held it in 5 quarters. The position peaked at $20.2M in Q4 2023. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

CSS LLC reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
CSS LLC sold 343,845 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $20.2M.
CSS LLC first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2021 and held it in 5 quarters.
CSS LLC's Mirati Therapeutics, Inc. Common Stock position peaked at $20.2M in Q4 2023.
2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on CSS LLC's 13F filing for Q1 2024, filed 15 May 2024.